Julia R. Brown is a member of the Board of Directors of Targacept, Inc., Labopharm, Inc., and MediQuest Therapeutics, Inc. She was a member of the founding Board of Directors of Trius Therapeutics, Inc. and continued to serve until its recent Series B financing. She remains on the Trius business advisory board. She was a member of the Board of Directors of Tanox, Inc. from 2005 until its acquisition by Genentech in 2007. She served on the business advisory board of CovX Pharmaceuticals from 2004 until its acquisition by Pfizer in 2008. Julia is a member of the board of CONNECT, an organization that fosters innovation, entrepreneurship and the formation of new companies. She serves on its public policy committee. Julia is Vice Chair of the Board of Trustees of the University of California, San Diego Foundation. Julia is a certified director. She is a Tech Coast Angel, a member of BIOCOM, Corporate Director’s Forum, and Athena.

From 2000-2003, Julia was Executive Vice President of Amylin Pharmaceuticals, Inc. and Advisor to the CEO until 2008. Prior to joining Amylin, Julia was Executive Vice President of Dura Pharmaceuticals, Inc. She was with Dura from 1995-1999. Julia spent over 25 years with Eli Lilly and Company in progressively more senior roles. From 1992-1994, Julia was Vice President of IVAC Corporation and General Manager of its Vital Signs Division (a Lilly subsidiary). She was Vice President of Worldwide Marketing for Hybritech (another Lilly subsidiary), and led global marketing from1986-1992. She held a variety of positions in the pharmaceutical division, including eight years in the Company’s international division. She did basic research in antimicrobials from 1969-1973. Julia is a graduate of Louisiana Tech University where she studied microbiology and biochemistry.